Ignite Creation Date:
2024-05-06 @ 8:05 PM
Last Modification Date:
2024-10-26 @ 3:20 PM
Study NCT ID:
NCT06248671
Status:
RECRUITING
Last Update Posted:
2024-07-03
First Post:
2024-01-19
Brief Title:
Prophylactic Treatment With Atorvastatin for Episodic Migraine
Sponsor:
St Olavs Hospital
Organization:
St Olavs Hospital
Study Overview
Official Title:
EpisodicStatinMig A Multicentre Triple Blind Placebo Controlled Parallel Group Study of Atorvastatin in Episodic Migraine
Status:
RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
EStatinMig
Brief Summary:
The main objective of this study is to see whether the favorable preventative effect of Atorvastatin 40mg per day in episodic migraine that was found previously in three smaller randomized controlled cross-over studies can be confirmed in a larger multicenter randomized controlled parallel group study In addition it will be investigated whether 1 there is an effect of a daily dose of 20mg Atorvastatin 2 whether the favorable side effect profile seen in previous studies can be confirmed and whether it is even better with the smaller dose and 3 estimating the cost of Atorvastatin treatment considering cost of medicine cost of acute attack medicine and cost of lost worktime
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None